We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

134 hedge funds and large institutions have $629M invested in Arena Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 43 increasing their positions, 47 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $571M → $629M (+$57.6M)

9% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 47

4% less funds holding

Funds holding: 140134 (-6)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

44% less call options, than puts

Call options by funds: $34.3M | Put options by funds: $61.2M

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
134
Holders Change
-6
Holders Change %
-4.29%
% of All Funds
3.89%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
22
Increased
43
Reduced
47
Closed
28
Calls
$34.3M
Puts
$61.2M
Net Calls
-$26.9M
Net Calls Change
-$5.34M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$176M +$13.3M +255,149 +9%
Vanguard Group
2
Vanguard Group
Pennsylvania
$81.7M +$4.38M +83,764 +6%
BFA
3
BlackRock Fund Advisors
California
$47.2M -$902K -17,266 -2%
State Street
4
State Street
Massachusetts
$41.9M -$3.83M -73,278 -9%
BIT
5
BlackRock Institutional Trust
California
$35.4M -$1.37M -26,203 -4%
O
6
OppenheimerFunds
New York
$35.1M
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$22.6M +$13.4M +256,130 +198%
SC
8
Samlyn Capital
New York
$21.4M +$7.25M +138,693 +61%
Northern Trust
9
Northern Trust
Illinois
$18.5M +$452K +8,648 +3%
Norges Bank
10
Norges Bank
Norway
$9.82M
Bank of New York Mellon
11
Bank of New York Mellon
New York
$7.3M -$32K -612 -0.5%
Invesco
12
Invesco
Georgia
$7.14M +$1.78M +34,037 +39%
DM
13
Deerfield Management
New York
$7.12M
Geode Capital Management
14
Geode Capital Management
Massachusetts
$6.3M +$434K +8,304 +8%
Deutsche Bank
15
Deutsche Bank
Germany
$6.11M -$86.5K -1,656 -2%
BA
16
BlackRock Advisors
Delaware
$6.09M +$4.64M +88,775 +577%
TCIM
17
TIAA CREF Investment Management
New York
$5.9M -$131K -2,505 -2%
TA
18
Teachers Advisors
New York
$5.26M +$3.13M +59,829 +198%
CS
19
Credit Suisse
Switzerland
$5.07M +$90.2K +1,726 +2%
Morgan Stanley
20
Morgan Stanley
New York
$4.02M -$3.94M -75,417 -52%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$3.86M -$51.4K -984 -2%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$3.82M +$3.41M +65,344 New
BIM
23
BlackRock Investment Management
Delaware
$3.6M -$81.2K -1,554 -2%
GC
24
Guggenheim Capital
Illinois
$3.46M -$227K -4,350 -7%
VanEck Associates
25
VanEck Associates
New York
$3.44M +$371K +7,095 +14%

ARNA Hedge Fund Activity: Q4 2013 in Review

134 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2013, worth a combined $629M — up 10% from $571M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of ARNA and 22 opened new positions — a net loss of 6 holders — while 47 trimmed existing stakes and 43 added.

The largest buyer was Susquehanna International Group, adding an estimated $13.4M. The largest seller was Capital World Investors, exiting entirely with an estimated $26.4M sold.

  • 134 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2013, down from 140 in Q3 2013.
  • Funds reported $629M of Arena Pharmaceuticals Inc stock for Q4 2013, up 10% quarter-over-quarter.
  • 22 funds opened new Arena Pharmaceuticals Inc positions in Q4 2013 and 28 closed out, a net change of -6 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q4 2013 was Susquehanna International Group, an estimated $13.4M added.
  • The largest Arena Pharmaceuticals Inc seller in Q4 2013 was Capital World Investors, an estimated $26.4M sold.

Based on aggregated 13F filings for Q4 2013.